Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.3346 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OC
InChI
InChIKey=HYIMSNHJOBLJNT-UHFFFAOYSA-N
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.3346 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB01115Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020198s023lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB01115
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020198s023lbl.pdf
Nifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. Nifedipine is sold under the brand names Adalat and Procardia among others. Nifedipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure. Nifedipine is used for the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3368504
Curator's Comment: nifedipine can easily cross the blood-brain barrier in the rat
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: http://www.genome.jp/dbget-bin/www_bget?D00437 |
2.0 µM [IC50] | ||
Target ID: CHEMBL1940 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2435904 |
1.0 nM [Ki] | ||
Target ID: CHEMBL1075226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25893973 |
37.5 µM [IC50] | ||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24399740 |
7.8 µM [IC50] | ||
Target ID: Cholangiocarcinoma, Mz-ChA-1, human Sources: https://www.ncbi.nlm.nih.gov/pubmed/21179572 |
15.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROCARDIA Approved UseI. Vasospastic Angina
PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by
any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment
elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically
demonstrated coronary artery spasm. In those patients who have had angiography, the presence of
significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina,
provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical
presentation suggests a possible vasospastic component but where vasospasm has not been
confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to
nitrates and/or adequate doses of beta blockers.
II. Chronic Stable Angina
(Classical Effort-Associated Angina)
PROCARDIA is indicated for the management of chronic stable angina (effort-associated
angina) without evidence of vasospasm in patients who remain symptomatic despite adequate
doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. Launch Date3.78518405E11 |
|||
Primary | PROCARDIA Approved UseI. Vasospastic Angina
PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by
any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment
elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically
demonstrated coronary artery spasm. In those patients who have had angiography, the presence of
significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina,
provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical
presentation suggests a possible vasospastic component but where vasospasm has not been
confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to
nitrates and/or adequate doses of beta blockers.
II. Chronic Stable Angina
(Classical Effort-Associated Angina)
PROCARDIA is indicated for the management of chronic stable angina (effort-associated
angina) without evidence of vasospasm in patients who remain symptomatic despite adequate
doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. Launch Date3.78518405E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
78.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3609112/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIFEDIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
148 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3609112/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIFEDIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3609112/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIFEDIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8% |
unknown |
NIFEDIPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
90 mg single, oral Overdose |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: M Population Size: 1 Sources: |
Disc. AE: Tachycardia, Hyperglycemia... AEs leading to discontinuation/dose reduction: Tachycardia (grade 5, 1 patient) Sources: Hyperglycemia (grade 5, 1 patient) |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Disc. AE: Hypotension, Acidosis... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Sources: Acidosis (1 patient) Hyperglycemia (1 patient) |
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Co-administed with:: ethanol Sources: |
unknown, 37 years n = 1 Health Status: unknown Age Group: 37 years Sex: M Population Size: 1 Sources: |
Disc. AE: Intestinal infarction... AEs leading to discontinuation/dose reduction: Intestinal infarction (1 patient) Sources: |
300 mg single, oral Overdose |
unknown, 54 years n = 1 Health Status: unknown Condition: attempt to commit suicide Age Group: 54 years Sex: F Population Size: 1 Sources: |
Disc. AE: Reflex tachycardia... AEs leading to discontinuation/dose reduction: Reflex tachycardia (1 patient) Sources: |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypotension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Sources: Tachycardia (1 patient) Flushing (1 patient) |
900 mg single, oral Overdose |
unhealthy, 59 years n = 1 Health Status: unhealthy Condition: with a history of angina, left bundle branch block, and depression Age Group: 59 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypotension, Hyperglycemia... AEs leading to discontinuation/dose reduction: Hypotension (grade 4, 1 patient) Sources: Hyperglycemia (1 patient) |
180 mg 1 times / day steady, oral Highest studied dose Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, adult n = 1000 Health Status: unhealthy Condition: hypertension and angina Age Group: adult Sex: unknown Population Size: 1000 Sources: |
DLT: Edema... Dose limiting toxicities: Edema (30%) Sources: |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: Vomiting (1 patient) Headache (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperglycemia | grade 5, 1 patient Disc. AE |
90 mg single, oral Overdose |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: M Population Size: 1 Sources: |
Tachycardia | grade 5, 1 patient Disc. AE |
90 mg single, oral Overdose |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: M Population Size: 1 Sources: |
Acidosis | 1 patient Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Hyperglycemia | 1 patient Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Hypotension | 1 patient Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Intestinal infarction | 1 patient Disc. AE |
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Co-administed with:: ethanol Sources: |
unknown, 37 years n = 1 Health Status: unknown Age Group: 37 years Sex: M Population Size: 1 Sources: |
Reflex tachycardia | 1 patient Disc. AE |
300 mg single, oral Overdose |
unknown, 54 years n = 1 Health Status: unknown Condition: attempt to commit suicide Age Group: 54 years Sex: F Population Size: 1 Sources: |
Flushing | 1 patient Disc. AE |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Hypotension | 1 patient Disc. AE |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Tachycardia | 1 patient Disc. AE |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Hyperglycemia | 1 patient Disc. AE |
900 mg single, oral Overdose |
unhealthy, 59 years n = 1 Health Status: unhealthy Condition: with a history of angina, left bundle branch block, and depression Age Group: 59 years Sex: M Population Size: 1 Sources: |
Hypotension | grade 4, 1 patient Disc. AE |
900 mg single, oral Overdose |
unhealthy, 59 years n = 1 Health Status: unhealthy Condition: with a history of angina, left bundle branch block, and depression Age Group: 59 years Sex: M Population Size: 1 Sources: |
Edema | 30% DLT |
180 mg 1 times / day steady, oral Highest studied dose Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, adult n = 1000 Health Status: unhealthy Condition: hypertension and angina Age Group: adult Sex: unknown Population Size: 1000 Sources: |
Headache | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Nausea | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Vomiting | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak [IC50 186 uM] | ||||
weak [IC50 472 uM] | ||||
weak | ||||
weak | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11560876/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11560876/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11560876/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/14570758/ |
yes | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: [ADALAT® XL®PRODUCT MONOGRAPH]: Use of ADALAT XL with drugs that result in strong inhibition of CYP 3A4, such as ketoconazole, clarithromycin, ritonavir, may lead to increased plasma levels of nifedipine and associated serious adverse events. Such concomitant use should be avoided. |
|||
minor | ||||
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[Sexual impotence caused by nifedipine]. | 1992 Jan 18 |
|
The calcium channel antagonist nifedipine causes confusion when used to treat opiate withdrawal in morphine-dependent patients. | 1992 Nov |
|
A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. | 1992 Oct |
|
Lindane-induced convulsions in NMRI and OF1 mice: antagonism with (+)MK-801 and voltage-dependent calcium channel blockers. | 1992 Oct 16 |
|
Cortical blindness after nifedipine treatment. | 1992 Sep 19 |
|
Nifedipine-induced hypotensive shock. | 1997 Dec |
|
[The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension]. | 1998 Mar |
|
The influence of nifedipine on blood-brain barrier permeability during bicuculline-induced seizures. | 1999 Aug |
|
Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. | 1999 Jun |
|
Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing. | 1999 Nov |
|
Effects of the antihypertensive drug nifedipine on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes. | 1999 Nov |
|
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. | 1999 Oct |
|
Effects of a slow-release nifedipine on 24-hour ambulatory blood pressure and ischemic changes on 24-hour ambulatory electrocardiogram in patients with severe coronary artery disease. | 2000 |
|
Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. | 2000 |
|
[Effects of calcium antagonists on atherosclerosis progression and intima media thickness]. | 2000 |
|
Life threatening coronary artery spasm in childhood Kimura's disease. | 2000 Aug |
|
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
Nifedipine and haemolytic anaemia. | 2000 Feb |
|
Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. | 2000 Feb |
|
Immunolocalizaiton of c-Myc and bcl-2 proto-oncogene products in gingival hyperplasia induced by nifedipine and phenytoin. | 2000 Jan |
|
Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. | 2000 Jan 25 |
|
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). | 2000 Jul 29 |
|
Characterization of nifedipine-resistant calcium current in neonatal rat ventricular cardiomyocytes. | 2000 Nov |
|
Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. | 2000 Oct |
|
Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. | 2000 Oct 1 |
|
Adverse neurologic events associated with rebound hypertension after using short-acting nifedipine in childhood hypertension. | 2001 Dec |
|
Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. | 2001 Feb |
|
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. | 2001 Feb |
|
Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. | 2001 Mar |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. | 2002 Aug |
|
Evaluation of the safety of short-acting nifedipine in children with hypertension. | 2002 Jan |
|
Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. | 2002 Jul |
|
Depression--an adverse event with nifedipine. | 2002 Nov |
|
In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. | 2003 |
|
[Pathogenetic basis of the application of calcium antagonists in the treatment of recurrent peptic ulcer]. | 2003 |
|
Requirement of calcium and phosphate ions in expression of sodium-dependent vitamin C transporter 2 and osteopontin in MC3T3-E1 osteoblastic cells. | 2003 Jun 17 |
|
ETA receptor-mediated Ca2+ mobilisation in H9c2 cardiac cells. | 2003 Mar 1 |
|
Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells. | 2003 Nov |
|
Induction of ABCC3 (MRP3) by pregnane X receptor activators. | 2003 Nov |
|
Fatality from administration of labetalol and crushed extended-release nifedipine. | 2003 Oct |
|
Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension. | 2004 May |
|
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. | 2004 Nov |
|
Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells. | 2005 Apr |
|
Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. | 2005 Apr |
|
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. | 2005 Apr |
|
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes. | 2005 Sep |
|
Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo. | 2005 Sep-Oct |
Sample Use Guides
Therapy should be initiated with the 10 mg capsule. The starting dose is one 10 mg capsule, swallowed whole, 3 times/day. The usual effective dose range is 10–20 mg three times daily. Some patients, especially those with evidence of coronary artery spasm, respond only to higher doses, more frequent administration, or both. In such patients, doses of 20–30 mg three or four
times daily may be effective. Doses above 120 mg daily are rarely necessary. More than 180 mg per day is not recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923790
About 50% of the Ca(v) current was blocked by 10 uM of the L-type channel blocker nifedipine in human induced pluripotent stem cell-derived neurons.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 23:17:47 UTC 2023
by
admin
on
Thu Jul 06 23:17:47 UTC 2023
|
Record UNII |
I9ZF7L6G2L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08GA01
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
FDA ORPHAN DRUG |
57991
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
NDF-RT |
N0000000069
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
WHO-ATC |
C08GA01
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
WHO-VATC |
QC08CA55
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
LIVERTOX |
NBK548324
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
NDF-RT |
N0000007556
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
WHO-ATC |
C08CA55
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
WHO-ATC |
C08CA05
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
WHO-VATC |
QC08CA05
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
22.2
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
||
|
NDF-RT |
N0000175421
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NIFEDIPINE
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | Description. A yellow, crystalline powder.Solubility. Nifedipine is practically insoluble in water; freely soluble in acetone R; sparingly soluble in dehydrated ethanol R.Category. Cardiovascular drug; calcium-channel blocking agent.Storage. Nifedipine should be kept in a tightly closed container, protected from light.Additional information. CAUTION: Nifedipine decomposes on exposure to daylight, artificial light of certain wavelengths, andultraviolet light.Requirements: Nifedipine contains not less than 98.0% and not more than 102.0% of C17H18N2O6, calculated with reference to the driedsubstance.Note: Throughout the monograph perform the tests and the assay in the dark or under a suitable fluorescent light, using lowactinicglassware. | ||
|
DB01115
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
244-598-3
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
3222
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
DTXSID2025715
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
D009543
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
C29290
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
I9ZF7L6G2L
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
7565
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
M7883
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | Merck Index | ||
|
I9ZF7L6G2L
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
SUB09253MIG
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
7775
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
21829-25-4
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
4485
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
7417
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | RxNorm | ||
|
2514
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
NIFEDIPINE
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
CHEMBL193
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
757242
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
1922
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
Nifedipine
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
100000090371
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY | |||
|
1463508
Created by
admin on Thu Jul 06 23:17:48 UTC 2023 , Edited by admin on Thu Jul 06 23:17:48 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
DEGRADENT -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
DEGRADENT -> PARENT |
LIGHT INDUCED DEGRADENT
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |